-transparent.png){kind=logo}
We investigated the effect of RU41740, a glycoprotein extracted from Klebsiella pneumoniae and possessing immunomodulating properties, on human neutrophil functions in vitro and ex vivo. Our in vitro results showed that RU41740 increased complement- and Fc receptor-dependent phagocytosis. Moreover, the drug enhanced the oxidative metabolism (assessed by chemiluminescence) both in resting and stimulated cells; in the latter case the RU41740-induced enhancement was observed when neutrophils were stimulated with opsonized particles of N-formyl-methionyl-leucyl-phenylalanine (FMLP) but not when phorbol myristate acetate was used. Using otherwise effective experimental conditions, RU41740 did not affect spontaneous or FMLP-induced neutrophil migration. For the ex vivo experience we tested neutrophils of ten elderly subjects with a previously demonstrated phagocytic defect. These subjects were treated orally with RU41740 at a daily dose of 2 mg for 1 week during the first month, and of 1 mg for 1 week in the second month. In this population, RU41740 was able to restore the impaired phagocytic activity and to induce a significant increase of spontaneous chemiluminescence (CL); stimulated CL was also positively influenced. These effects on neutrophils provide new explanatory bases for the immunostimulatory activity of RU41740.
F Capsoni, and
F Minonzio, and
E Venegoni, and
A M Ongari, and
P L Meroni, and
G Guidi, and
C Zanussi
January 1984,
Advances in experimental medicine and biology,
F Capsoni, and
F Minonzio, and
E Venegoni, and
A M Ongari, and
P L Meroni, and
G Guidi, and
C Zanussi
January 1992,
Clinical therapeutics,
F Capsoni, and
F Minonzio, and
E Venegoni, and
A M Ongari, and
P L Meroni, and
G Guidi, and
C Zanussi
January 1982,
International archives of allergy and applied immunology,
F Capsoni, and
F Minonzio, and
E Venegoni, and
A M Ongari, and
P L Meroni, and
G Guidi, and
C Zanussi
January 1989,
Diagnostic microbiology and infectious disease,
F Capsoni, and
F Minonzio, and
E Venegoni, and
A M Ongari, and
P L Meroni, and
G Guidi, and
C Zanussi
July 1988,
The American journal of pathology,
F Capsoni, and
F Minonzio, and
E Venegoni, and
A M Ongari, and
P L Meroni, and
G Guidi, and
C Zanussi
January 1991,
Chemotherapy,
F Capsoni, and
F Minonzio, and
E Venegoni, and
A M Ongari, and
P L Meroni, and
G Guidi, and
C Zanussi
August 1981,
Infection and immunity,
F Capsoni, and
F Minonzio, and
E Venegoni, and
A M Ongari, and
P L Meroni, and
G Guidi, and
C Zanussi
January 1992,
Immunopharmacology,
F Capsoni, and
F Minonzio, and
E Venegoni, and
A M Ongari, and
P L Meroni, and
G Guidi, and
C Zanussi
January 1993,
Pediatric research,
F Capsoni, and
F Minonzio, and
E Venegoni, and
A M Ongari, and
P L Meroni, and
G Guidi, and
C Zanussi
October 1986,
The Journal of pediatrics,
